Page 38 - Virtual Vascular Vol 11
P. 38

Sodium-glucose transport protein 2 (SGLT2) inhibitors, such as canagliflozin, dapagliflozin,
    empagliflozin, and ertugliflozin, are a class of type 2 diabetic drugs that alter essential
    physiology of the nephron and inhibits reabsorption of glucose in the kidney.


         Drugs





















































































        38
   33   34   35   36   37   38   39   40   41   42   43